180 Wealth Advisors LLC Buys 11,060 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

180 Wealth Advisors LLC lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 192.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,798 shares of the biopharmaceutical company’s stock after acquiring an additional 11,060 shares during the period. 180 Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,118,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Financial Advantage Inc. grew its holdings in Bristol-Myers Squibb by 0.7% in the 3rd quarter. Financial Advantage Inc. now owns 73,601 shares of the biopharmaceutical company’s stock valued at $3,732,000 after buying an additional 487 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after purchasing an additional 7,178,698 shares in the last quarter. Cutler Investment Counsel LLC grew its holdings in shares of Bristol-Myers Squibb by 25.4% during the 3rd quarter. Cutler Investment Counsel LLC now owns 183,435 shares of the biopharmaceutical company’s stock worth $9,302,000 after purchasing an additional 37,150 shares in the last quarter. Premier Asset Management LLC grew its holdings in shares of Bristol-Myers Squibb by 15.1% during the 3rd quarter. Premier Asset Management LLC now owns 5,364 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 703 shares in the last quarter. Finally, Keeley Teton Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $214,000. 83.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb stock traded up $0.33 during trading on Friday, reaching $67.11. 200,779 shares of the company were exchanged, compared to its average volume of 15,257,604. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $67.09. The business has a 50-day moving average price of $62.71 and a 200-day moving average price of $53.14. The firm has a market capitalization of $108.25 billion, a price-to-earnings ratio of 16.86, a P/E/G ratio of 0.85 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. During the same period in the previous year, the firm earned $1.09 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. On average, equities research analysts forecast that Bristol-Myers Squibb Co will post 4.47 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 2.68%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend is Thursday, January 2nd. Bristol-Myers Squibb’s payout ratio is presently 45.23%.

BMY has been the topic of several recent research reports. Argus raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Friday, December 13th. Wolfe Research set a $66.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Friday, December 13th. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 19th. Finally, Mizuho started coverage on Bristol-Myers Squibb in a research report on Monday, November 25th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $61.69.

In other news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the transaction, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now directly owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.